TABLE 4.
Summary of the immunohistochemical studies, HPV DNA probe, and clonality tests performed on 12, 4, and 9 cases (Fig. 5) (cases 1 to 8 with different histologic features; cases 9 to 14 with similar histologic features)
| Patient no. | Vimentin | CEA | ER | PR | p16 | ISH and PCR DNA/RNA in situ analyses for high-risk HPV | Clonality | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EnM | EnCX | EnM | EnCX | EnM | EnCX | EnM | EnCX | EnM | EnCX | EnM | EnCX | EnM | EnCX | |
| 1 | + | + | – | – | + | + | + | + | 60% + | 10% + | N/A | N/A | LOH of D1S201 D10D215 w/MSI | LOH of D10S215 |
| 2 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | LOH of D3S1300, IL2RB, TP53, D6S250 | LOH of ER, borderline of D10S541 |
| 3 | + | – | – | – | + | + | + | + | 80% + | 30% + | – | – | LOH of D1S201, TP53, D17D791, D17S796, ER; MSI in D10S541 | LOH of D3S1300, D18S483, D17S791, ER; MSI of D10S215, TP53, D6S250 |
| 4 | + | + | + | – | + | + | + | + | 50% + | 80% + | N/A | N/A | No LOH | LOH borderline of D18S483, TP53 |
| 5 | + | + | – | – | + | + | + | + | 5% + | 20% + | N/A | N/A | LOH of ER | LOH of D10S541 |
| 6 | + | + | – | – | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 7 | + | + | – | – | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 8 | + | + | – | – | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 9 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | LOH of D10S215 | LOH of D10S215 |
| 10 | + | + | – | – | + | + | + | + (normal gland +) | 10% + | 50% + | N/A | N/A | N/A | N/A |
| 11 | Focal + | – | – | – | Focal + | + | + | Focal + | 40% + | 40% + | ISH equivocal, PCR − | ISH equivocal, PCR − | N/A | N/A |
| 12 | – | Focal + | – | Focal + | + | + | – | – | 100% + | 100% + | N/A | N/A | LOH of IL2RBD6S250 | No LOH |
| 13 | – | – | + | + | – | – | – | – | 100%− | 100% + | + | + | LOH of D10S215 | LOH of D10S215 |
| 14 | + | + | – | – | + | + | – | + | 30% + | 30% + | – | – | No LOH | LOH of TP53,D10S541 |
CEA indicates carcinoembryonic antigen; ER, estrogen receptor; EnCX indicates endocervix; EnM, endometrium; HPV, human papillomavirus; LOH, loss of heterozygosity; N/A, not available; PCR, polymerase chain reaction; PR, progesterone receptor.